NICHOLAS OSWALD IANNOTTI MD FACP NPI 1154360642

NPI Details

Nicholas Oswald Iannotti, MD, FACP is a hematology and oncology internal medicine in Port St Lucie, FL with 43 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Nicholas Oswald Iannotti, MD, FACP NPI is 1154360642. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE
Graduation Year:1983

The provider's business location address is:

1871 SE TIFFANY AVE
SUITE 100
PORT ST LUCIE, FL
ZIP 34952-585
Phone: (772) 335-5666
Fax: (772) 335-4826

The NPI 1154360642 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Folic acid level, serum (HCPCS:82746)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Manual urinalysis test with examination using microscope, non-automated (HCPCS:81000)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Anticoagulant management of patient taking warfarin (HCPCS:93793)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Blood test, clotting time (HCPCS:85610)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Magnesium level (HCPCS:83735)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Collection of blood sample from implanted device (HCPCS:36591)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Drawing of blood for a medical problem (HCPCS:99195)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Ct scan of chest with contrast (HCPCS:71260)
• Stool analysis for blood, by peroxidase activity (HCPCS:82272)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Blood creatinine level (HCPCS:82565)
• Ct scan of abdomen and pelvis before and after contrast (HCPCS:74178)
• Ct scan of chest without contrast (HCPCS:71250)
• Urea nitrogen level to assess kidney function, quantitative (HCPCS:84520)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Liver function blood test panel (HCPCS:80076)
• Prostate cancer screening; prostate specific antigen test (psa) (HCPCS:G0103)

The enumeration date for this NPI number is 6/6/2006 and was last updated on 6/15/2010.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.